We used the National Institutes of Health (NIH) criteria for the diagnosis, classification and scoring of chronic GVHD (cGVHD) to reevaluate patients with cGVHD originally diagnosed using classic criteria. We retrieved data from 236 patients diagnosed with cGVHD on the basis of classic criteria. Excluding 20 'liver-alone' patients, we re-categorized 216 patients in keeping with the NIH criteria. Twenty patients were reclassified as having acute GVHD and 196 patients as having cGVHD (170 'classic chronic' (Cl-Ch) and 26 'overlap chronic' (Ov-Ch)). The 5-year GVHD-specific survival (GSS) was significantly different between the two cGVHD subtypes, specifically 87.3% for Cl-Ch vs 70.2% for Ov-Ch (P ¼ 0.006). The NIH severity criteria were effective in expecting 5-year GSS rates at both the onset (93.5, 81.3 and 79.7% (P ¼ 0.047)) and peak intensity of the disease (100, 89.7 and 78.7% (P ¼ 0.004) for the mild, moderate and severe grade, respectively). Multivariate analysis showed that NIH severity criteria were independently significant prognostic factors for GSS (mild vs moderate, HR 4.35, P ¼ 0.036; mild vs severe, HR 5.25, P ¼ 0.020). Our results support the role of the NIH criteria in classifying cGVHD and in assessing the severity of the disease to predict patient prognosis of cGVHD.
Introduction
Chronic GVHD (cGVHD) is one of the late complications of allogeneic hematopoietic cell transplantation (allo-HCT), and can have serious effects on the quality of life, leading to debilitating consequences for allo-HCT patients recovering successfully from a life-threatening hematological disease. [1] [2] [3] [4] [5] The growing use of hematopoietic stem cells collected from peripheral blood instead of BM, 6, 7 expansion of the donor population beyond HLA-identical siblings 8, 9 and the increasing age of allo-HCT recipients 10, 11 have led to the escalating incidence of cGVHD. Although several studies have examined the effects of cGVHD on recurrence of disease and quality of life of patients, effective criteria for accurate classification and stratification of severity are limited. The staging proposed by the Seattle Group in 1980, which categorizes episodes of cGVHD as 'limited' or 'extensive', is the most commonly used classification to date. 12 Although this Seattle staging system has been effectively used to predict the prognosis of patients with cGVHD, [13] [14] [15] [16] [17] these classic criteria have several difficulties in terms of the insufficiency of patient information regarding the extent of the disease, the organ involved, functional impairment, prognosis and survival. The Seattle criteria is also thought to be poorly reproducible and insufficient to discern patients in need of systemic therapy, which makes it complicated to design better clinical trials and facilitate communication among centers based on classic criteria. 18 The National Institutes of Health (NIH) proposed new criteria for the diagnosis, classification and stratification of cGVHD patients after allo-HCT in 2005 to provide a tool to better describe the extent, severity and functional status of patients diagnosed with cGVHD. 19 A few retrospective analyses have been reported to validate these newly defined parameters as predictors of important end points, such as the need for immunosuppression, functional status, quality of life, nonrelapse mortality and survival. Jagasia et al. 20 analyzed the clinical feasibility of the new criteria in a study on 110 patients subjected to allo-HCT for a hematological malignancy. The OS rates differed markedly among the subtypes of GVHD on the basis of NIH classification criteria, but the grading system failed to reveal significant differences in OS between each subgroup. Recent studies by Cho et al. 21 suggest that the grade by the NIH severity criteria and that by the revised Seattle classification system are significant independent factors for predicting GVHDspecific survival (GSS). 22, 23 However, the classical parameters for GSS, including level of serum bilirubin at the onset of GVHD and mode of onset, were not included in the multivariate analysis.
In this study, we assessed the clinical feasibility of the NIH criteria in the severity grade stratification of patients originally diagnosed with cGVHD after allo-HCT on the basis of classic criteria in terms of GSS, and determined whether the incorporation of grade by the NIH criteria in a model with established risk factors improves prediction of GSS.
Patients and methods

Patient selection
From December 1994 to April 2008, 618 patients underwent allogeneic hematopoietic cell transplantation (HCT) at the Asan Medical Center, Seoul, Korea. Patient details were recorded in the Asan Medical Center BMT registry and we retrieved data of 236 patients with GVHD, who were classified as 'chronic' on the basis of time after transplantation, that is, those presenting clinical symptoms, signs or laboratory features of GVHD after day 100. Episodes of GVHD that developed after donor lymphocyte infusion or second HCT were excluded.
Among the 236 patients, GVHD episodes in 20 cases in which involvement was confined to the liver alone could not be classified as cGVHD using the NIH criteria. Accordingly, a total of 216 patients were included for the retrospective reclassification and grading of their GVHD episodes on the basis of NIH criteria.
Details of transplantation
Patients received either a myeloablative (CY 60 mg/kg once daily i.v. on days 3 and 2 (total dose 120 mg/kg) and BU 3.2 mg/kg once daily i.v. on days À7, À6, À5 and À4 (total dose 12.8 mg/kg) or fludarabine 30 mg/m 2 once daily i.v. on days À6, À5, À4, À3 and À2 (total dose 150 mg/m 2 ) and BU 3.2 mg/kg once daily i.v. on days À7, À6, À5 and À4 (total dose 12.8 mg/kg)) or non-myeloablative (fludarabine 30 mg/m 2 once daily i.v. on days À7, À6, À5, À4, À3 and À2 (total dose 180 mg/m 2 ), BU 3.2 mg/kg once daily i.v. on days À7 and À6 (total dose 6.4 mg/kg) and anti-thymocyte globulin 1.25 mg/kg (for sibling HLA-matched donor) or 3 mg/kg (for unrelated donor) once daily i.v. on days À4, À3 and À2 (total dose 3.75 mg/kg for sibling HLA-matched donor, 9 mg/kg for unrelated donor)) regimen as conditioning therapy. CYA, either administered alone or in combination with MTX, was used for GVHD prophylaxis.
Reclassification and grading of cGVHD All the GVHD episodes of patients were reclassified as 'classic acute' (Cl-Ac), 'persistent, recurrent or late onset acute' (PRL-Ac), 'classic chronic' (Cl-Ch) and 'overlap chronic' (Ov-Ch) at the time of worst clinical status for each patient. Assignment of acute GVHD features was confined to 'common symptoms' (defined by NIH criteria) involving the skin/mouth/gastrointestinal tract without any presence of cGVHD symptoms and signs. Patients showing both acute GVHD and cGVHD features were classified as 'Cl-Ch' if symptoms/signs of acute GVHD features disappeared at least 2 weeks before the onset of cGVHD features, and as 'Ov-Ch' if the time interval between the onsets of acute GVHD and cGVHD features was o2 weeks.
For patients classified as 'Cl-Ch' or 'Ov-Ch', cGVHD severity for each involved organ was scored using the NIH severity criteria. At each time point of assessment, a grade of 'mild', 'moderate' or 'severe' was assigned to each cGVHD episode on the basis of both the number of involved organs/sites and the score for each affected organ/ site. For each patient, grade was evaluated twice during his/ her whole course of cGVHD-at the time of onset and at the time of peak intensity.
Statistical considerations
Baseline demographic characteristics and HCT-associated features of patients were collected from the record of the 'Asan Medical Center BMT registry'. Descriptive statistics, such as percentage/frequencies for categorical variables and means/medians/ranges for continuous variables, were applied to describe patient characteristics and the incidence/severity of cGVHD. Groups with nominal values were compared using the w 2 test. Overall survival time was measured from the onset of cGVHD to the date of last follow-up or death. We additionally evaluated the efficacy of the NIH criteria in stratifying and predicting the risk of cGVHD using GSS measurements. GSS was defined as the time from onset of cGVHD to death unrelated to relapse. Data were censored for patients who were alive at the last follow-up, for those who relapsed and for those who died of causes unrelated definitely to cGVHD-for example, for a patient who died of a traffic accident. The Kaplan-Meier method was adopted to evaluate the differences in GSS among risk groups. Proportional hazards assumptions were confirmed with Schoenfeld's tests.
Results
Patient characteristics
Among the 216 patients analyzed, 20 (9.3%) were reclassified as having acute GVHD on the basis of NIH criteria (7 'Cl-Ac' and 13 'PRL-Ac'), whereas 196 patients (90.7%) remained in the cGVHD category (170 'Cl-Ch' and 26 'Ov-Ch'). In all, 7 patients were proven to have been falsely diagnosed with cGVHD previously, and their diagnosis was corrected as 'Cl-Ac'.
We finally included the 196 patients with cGVHD (170 'Cl-Ch' and 26 'Ov-Ch') in evaluating the clinical significance of the NIH severity criteria. The median age of 196 patients (119 male and 77 female) was 35.5 years (range, 15-57). Patients' demographic and other characteristics related to HCT/cGVHD are listed in Table 1 .
Distribution of patients by cGVHD severity grade
In terms of grade by the NIH severity criteria at the time of onset, 70 patients (36%) were assigned to the mild, 64 (33%) to the moderate and 62 (31%) to the severe group. The distribution of patients was altered to 36 (18%) mild, 42 (22%) moderate and 118 (60%) severe GVHD cases when they were graded by the severity at peak intensity. Tables 2 and 3 show the number of patients per each involved organ and the distribution of patients according to severity by the NIH severity criteria.
The proportion of patients with severe GVHD was higher in the 'Ov-Ch' group than in the 'Cl-Ch' group. Within the 'Ov-Ch' group, 46% of patients were diagnosed with severe GVHD at the onset, compared with 29% patients in the 'Cl-Ch' group, although this difference was not statistically significant. Grading of severity at peak intensity revealed 81% severe cases in the 'Ov-Ch' group and 57% in the 'Cl-Ch' group (P ¼ 0.002).
Survival outcomes of GVHD patients
The median follow-up time was 37.1 months (range, 0.7-154.9). Sixty-four patients died and the total mortality rate was 32.7%. A total of 37 died among 42 patients who relapsed. Among 27 patients who died without any evidence of relapse, three cases were not considered as events because the cause of death was not directly related to cGVHD-1 patient died of complications of cerebral infarction and the other died of pneumonia, both of which broke out after the complete improvement of cGVHD Table 2 Involved organ and severity of chronic GVHD (no. of patients)
Total
At onset At peak severity without either evidence of relapse, and the other due to a traffic accident. The 5-year OS rate was 67.5% in the 'Cl-Ch' and 63.3% in the 'Ov-Ch' group (P ¼ 0.109). Median GSS was not yet reached, and the 5-year GSS rate was 85.1%. The 5-year GSS rates were significantly different between the two subtypes of cGVHD based on NIH classification criteria, specifically, 87.3% for the 'ClCh' group and 70.2% for the 'Ov-Ch' group (P ¼ 0.006) (Figure 1 ). Severity grades classified according to the NIH severity criteria showed significant differences in 5-year GSS rates, both at the onset and peak intensity of cGVHD (Figures 2a  and b) . Specifically, 5-year GSS rates were 93.5, 81.3 and 79.7% (P ¼ 0.047) at the onset, and 100, 89.7 and 78.7% at peak intensity (P ¼ 0.005) for the mild, moderate and severe grade, respectively. The 5-year OS rate showed a decreasing tendency as the severity of cGVHD at the onset was increased, although it was not significant (73.5, 63.0 and 63.8% (P ¼ 0.107)), whereas there was a significant difference in the 5-year OS rates among subgroups based on peak intensity (80.6, 71.1 and 61.2% (P ¼ 0.019) for the mild, moderate and severe grade, respectively).
Multivariate analysis
Multivariate analysis with Cox proportional hazards model was used to assess the relationship of the NIH severity criteria to GSS. Discrete covariates were age subgroup (45 years or less, more than 45 years), performance status subgroup at the onset of cGVHD (o80%, X80%), number of mismatches of HLA in locus A/B/DR (0-1, 2 or more), presence of previous acute GVHD, disease status at HCT (standard risk, high risk), type of transplant (sibling allogeneic, haploidentical and unrelated allogeneic), tissue transplanted (BM, peripheral blood), drug (Table 4) .
When the same variables were included in the multivariate analysis for OS, 'PS' (X80 vs o80%, HR 2.31, P ¼ 0.04), 'disease status at HCT' (standard risk vs high risk, HR 2.16, P ¼ 0.011) and 'manipulation for graft' (none vs mononuclear cell collection, HR 2.28, P ¼ 0.027) significantly affected OS. 'NIH global score at the onset of cGVHD' lost significance in predicting OS.
Discussion
Various efforts have been made to identify meaningful clinical parameters for the prognosis of patients with cGVHD and develop improved prognostic grading systems based on larger cohorts of patients. Akpek et al. 22 reported that the presence of thrombocytopenia, progressive-type onset and extent of skin involvement are related to GSS of patients with cGVHD, on the basis of data from 151 patients from IBMTR and three centers. IBMTR presented a grading system predictive of survival comprising the Karnofsky performance score, diarrhea, weight loss and cutaneous/oral involvement as independent prognostic variables. 24 Patients were stratified into three different risk groups (low/intermediate/high) on the basis of this system, with significant differences in treatment-related mortality rates between each group. The OS and disease-free survival rates of patients within the low-risk group were similar to or higher than those of patients without cGVHD.
The NIH proposed new criteria that were expected to be more relevant for the diagnosis and stratification of cGVHD in terms of predicting treatment-related survival and OS, including other purposes such as real-time description of cGVHD severity, extent of organ involvements, functional impairment, which potentially serves for stratification of therapeutic planning and provision of a new tool and end point for innovative clinical research. 19 The NIH criteria stratify episodes of GVHD into acute vs chronic groups, and are based not on the onset time but on clinical features, with the intention of overcoming the inappropriate expectation of patient survival in cases in which cGVHD was defined as episodes after 100 days following HCT.
In our study, 236 (38.2%) of 618 patients subjected to HCT were diagnosed with cGVHD according to the classic Seattle criteria. According to the definition of cGVHD defined in the NIH classification criteria, 19 the diagnosis of cGVHD cannot be made on the basis of liver biopsy alone but requires a distinctive manifestation in at least one other organ system. We excluded 20 cases in which organ involvement was confined to the liver alone. These cases could be classified neither as acute nor as chronic by definition of the NIH classification criteria. The OS rates were not significantly different between the two subgroups of cGVHD classified according to the NIH criteria (67.5% in 'Cl-Ch' and 63.3% in 'Ov-Ch'). The severity of cGVHD at onset did not significantly influence the difference of OS between groups, although the severity at peak intensity was helpful in discriminating groups with poor prognosis from others. However, the OS rate is influenced not only by the presence of GVHD but also by relapse and other causes. Consequently, this parameter was considered inappropriate to evaluate the influence of GVHD on patient survival. We selected GSS as a more appropriate end point than OS in evaluating the effects of cGVHD on patient survival.
The NIH severity criteria were appropriate for predicting the prognosis of patients with cGVHD classified on the basis of severity at onset and peak intensity. There was a trend of increased GSS rates among patients classified as mild at onset, compared with those classified as severe with the NIH scoring system. This finding suggests that the NIH system is very discriminative in predicting the prognosis of patients with cGVHD. Finally, there were no cGVHDrelated deaths during the first 5 years from the onset of disease among patients classified as mild at onset with no progress, suggesting that the prognosis of a cGVHD patient could be expected to be favorable if the onset of cGVHD was mild and no more aggravation was observed during the follow-up period.
Each variable comprising the NIH scoring system (for example, thrombocytopenia, skin/mouth/lung/gastrointestinal involvement) was also predictive for GSS in univariate analysis (data not shown). All these variables were included as scoring elements in the NIH scoring system and were not considered as separate ones for the multivariate analysis in our study.
We included patients who were diagnosed and followed up as having cGVHD on the basis of the classic Seattle criteria. Consequently, patients with clinical features typical of cGVHD were not included if the onset of the episode was earlier than day 100. The results may vary if we classify the subgroups and grade the severity of all patients with GVHD in our registry. To overcome this shortcoming, a prospective validation of the NIH criteria is in progress for allo-HCT recipients in our institute.
Patients who died of a cause unrelated definitely to cGVHD were censored while analyzing the GSS, although exclusion of patients for 'non-cGVHD reasons' may be arbitrary. If we included all 'non-relapse mortality' as events instead of 'cGVHD-related mortality', the discrimination of GSS by the NIH severity-at-onset criteria lost its significance in multivariate analysis (data not shown).
In our results, the NIH severity-at-onset criteria affected only GSS and not OS. Although this discrepancy between GSS and OS may be because of the difference in relapse rates, they were not significantly different among the three groups (22.9, 20.3 and 21.0% for the mild, moderate and severe group, P ¼ 0.814).
The major limitations of our retrospective study include heterogeneity in the principles of starting, modifying and tapering immunosuppressive therapy, and therefore present numerous difficulties in analyzing the clinical aspects of the use of immunosuppressants (for example, the relationship between duration of immunosuppression and improvement of cGVHD). On the basis of our results, a prospective study evaluating the feasibility of risk-stratified immunosuppressive therapy according to the severity grade using the NIH severity criteria is proposed.
Patients diagnosed with cGVHD after donor lymphocyte infusion or allo-HCT, which was carried out after failure of previous allo-HCT, were excluded from our analyses; further studies are warranted to evaluate the feasibility of NIH criteria among this patient population.
In summary, we propose that NIH classification criteria are effective in predicting the survival differences among groups, and that the severity grade at the onset of cGVHD based on the NIH severity criteria is a helpful clinical parameter in predicting prognosis of patients with cGVHD. A prospective evaluation of the clinical feasibility of NIH classification/severity criteria can be performed to develop a risk-adapted treatment strategy for cGVHD, on the basis of the revised strategy.
